2018 Drug Discovery Conference

April 23-24, 2018

Li Ka Shing Conference Center

Kenneth Frazier
CEO, Merck

Roy Vagelos, MD
Former CEO, Merck

Bob Bradway
CEO, Amgen

Jeff Leiden, MD
CEO, Vertex

Joe Jimenez
Former CEO, Novartis

Patrick Soon-Shiong, MD
CEO, NantWorks

Janet Woodcock, MD
Director, FDA Center for Drug Evaluation and Research (CDER)

Marc Tessier-Lavigne, PhD
President, Stanford University

Maria Millan, MD
President, California Institute of Regenerative Medicine

Gary Gibbons, MD
Director, NHLBI

Brian Kobilka, MD
2012 Nobel Prize (Chemistry)

Howard Bauchner, MD
Chief Editor, JAMA

John Keaney, MD
Associate Editor, NEJM

Paula Kiberstis, PhD
Senior Editor, Science

Peter Kirkpatrick, PhD
Chief Editor, Nature Reviews Drug Discovery

Organizing Committee

Joseph C. Wu, MD, PhD
Director, Stanford Cardiovascular Institute; Simon H. Stertzer Professor of Medicine and Radiology

Mark Mercola, PhD
Professor of Medicine (Cardiology)

Chaitan Khosla, PhD
Wells H. Rauser and Harold M. Petiprin Professor in the School of Engineering and Professor of Chemistry

Kuldev Singh, MD
Professor of Ophthalmology

Sanjay Malhotra, PhD
Associate Professor (Research) of Radiation Oncology



Katy Claiborn, PhD
Senior Researcher/Writer

Stanford Cardiovascular Institute

Stanford Cancer Institute

About the Stanford Cardiovascular Institute

The Institute currently consists of over 241 faculty members representing physicians, surgeons, engineers, basic and clinical researchers. The mission of the Institute is integrating fundamental research across disciplines and applying technology to prevent and treat cardiovascular disease.

To support cardiovascular research and education at CVI, please contact: **Cathy Hutton**, Senior Associate Director, Medical Center Development at cathy.hutton@stanford.edu

Cathy Hutton, MBA

For more information: http://med.stanford.edu/cvi/support-our-research.html and http://cvi.stanford.edu.